A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
Joshua Burshtein, MD
Advertisement
Joshua Burshtein, MD, is a resident physician in the Department of Dermatology at the University of Illinois Chicago.
Articles by Joshua Burshtein, MD
IL-17 inhibitors are highly effective, but many patients still require switching due to treatment failure, loss of response, or intolerance.
Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Accepts Addition of Bemotrizinol as First New Sunscreen Ingredient in 20 Years
2
Digital Twins in Dermatology: Your Patient’s Virtual Double Is Coming
3
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
4
Moving Past Dermal Filler Trends to Focus on Healthy Skin Aging
5